NeuroOne Q4 Revenue Jumps 38.4% as Annual Results Hit Top End of Guidance

Key Facts

1NeuroOne announced preliminary fiscal Q4 product revenue of $3.8 million, representing a 38.4% increase.

2Full-year product revenue reached $10.5 million, hitting the top end of the company's guidance range.

3The company secured a record $4.5 million purchase order for product inventory stocking.

NeuroOne Medical Technologies announced preliminary fiscal Q4 product revenue of $3.8 million, representing a 38.4% increase. According to a company statement on GlobeNewswire, full-year product revenue reached $10.5 million, hitting the top end of its previously issued guidance range.

The company secured a record $4.5 million purchase order for product inventory stocking, marking the largest order in its history. Regarding market performance, NMTC stock closed at $1.12 on October 2, 2026, after reaching a day high of $1.2 and a low of $0.9746 during that session.